<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011554</url>
  </required_header>
  <id_info>
    <org_study_id>IMT-TES-2016</org_study_id>
    <nct_id>NCT03011554</nct_id>
  </id_info>
  <brief_title>Telescope Exchange Study</brief_title>
  <acronym>TES</acronym>
  <official_title>A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes With Central Vision Impairment Associated With End-Stage Macular Degeneration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VisionCare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VisionCare, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      VisionCare's Implantable Miniature Telescope (IMT, intraocular telescope or telescope) is
      indicated for monocular implantation to improve vision in eyes of patients at least 65 years
      of age with severe to profound vision impairment caused by bilateral central scotomas
      associated with end-stage age-related macular degeneration (AMD).

      Patients with end-stage AMD who have undergone bilateral cataract removal and intraocular
      lens placement are currently contraindicated for telescope surgery.

      These patients have no viable therapy available to improve their vision.

      The objective of the TES pilot study is to evaluate the safety and effectiveness of
      implanting the intraocular telescope for improving vision in patients with bilateral
      end-stage age- related macular degeneration who are pseudophakic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Subjects will be followed up for three years post implantation</time_frame>
    <description>All reported adverse events will be summarized by number and percent of occurence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in best corrected distance visual acuity (BCDVA)</measure>
    <time_frame>Subjects will be followed up for three years post implantation</time_frame>
    <description>Change in LogMar BCDVA from pre-operative visit will be summarized starting at 1 month post-op.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Cell Density</measure>
    <time_frame>Subjects will be followed up for three years post implantation</time_frame>
    <description>ECD change and % change from preoperative visit will be summarized at each visit starting at 3 months post-op.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Increase in best corrected distance visual acuity (BCDVA)</measure>
    <time_frame>Subjects will be followed up for three years post implantation</time_frame>
    <description>Change in LogMar BCDVA from pre-operative visit will be summarized starting at 1 month post-op.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Implantable Miniature Telescope (IMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Miniature Telescope (IMT)</intervention_name>
    <description>Monocular implantation of the IMT.</description>
    <arm_group_label>Implantable Miniature Telescope (IMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have retinal findings of geographic atrophy or disciform scar with foveal involvement
             as determined by FA

          -  Be age 65 or older

          -  Have BCDVA between 20/160 to 20/800 (inclusive) on ETDRS chart

          -  Be pseudophakic in the eye selected for telescope implantation

          -  Agree to undergo pre-surgery training with a low vision specialist

          -  Achieve at least a 5-letter improvement on the ETDRS chart with an external telescope

          -  Agree to participate in postoperative vision training with a low vision specialist.

          -  Patients must be able to provide and sign a voluntary informed consent.

          -  Patients must not meet any of the exclusion criteria below.

        Exclusion Criteria:

          -  Stargardt's macular dystrophy

          -  Cognitive impairment that would interfere with the ability to understand
             instructions, follow directions, or prevent proper visual training/rehabilitation
             with the device.

          -  Any ophthalmic pathology that compromises fellow-eye peripheral vision

          -  A history of steroid-responsive rise in intraocular pressure (IOP), uncontrolled
             glaucoma, or preoperative IOP &gt;22mmHg while on maximum medication

          -  Known sensitivity to planned study concomitant medications.

          -  An ocular condition that predisposes the patient to eye rubbing.

          -  Patients participating in any other ophthalmic drug or device clinical trial during
             the time of this clinical investigation.

          -  Operative eye with:

               -  Evidence of active CNV or treatment of CNV within 6 months

               -  IOLs of the following types: PMMA, Crystalens, Tetraflex, Synchrony.

               -  Central anterior chamber depth (ACD) &lt; 3.0 mm; measurement of the ACD should be
                  taken from the posterior surface of the cornea (endothelium) to the anterior
                  surface of the IOL.

               -  Axial length &lt; 21 mm or &gt;27 mm

               -  Endothelial cell density (ECD) lower than 2300 cells/mm2 for subjects between
                  the ages 65-69, lower than 2000 cells/mm2 for subjects between the ages of
                  70-74, and lower than 1800 cells/mm2 for subjects 75 years old or greater.

               -  Corneal stromal or endothelial dystrophies, including guttata

               -  History of intraocular or corneal surgery (including DSEK) except cataract
                  removal and IOL placement

               -  History of complicated cataract surgery

               -  Compromised capsular bag (previous YAG posterior capsulotomy, evidence of
                  tearing)

               -  History of Radial Keratotomy

               -  Inflammatory ocular disease

               -  Pseudoexfoliation or zonular weakness

               -  Diabetic retinopathy

               -  Untreated retinal tears

               -  Retinal vascular disease

               -  Optic nerve disease

               -  A history of retinal detachment

               -  Intraocular tumor

               -  Retinitis pigmentosa

               -  Prior or expected ophthalmic related surgery within 30 days preceding telescope
                  implantation

               -  Any medical or ophthalmic condition that in the opinion of the investigator
                  renders the subject unsuitable for participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen S Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associated Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derek Kunimoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retinal Consultants of AZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Laron, PhD</last_name>
    <phone>(408) 664-0010</phone>
    <email>michal@visioncareinc.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boris Aradovsky, PhD</last_name>
    <phone>+972-3-928-4002</phone>
    <email>boris@visioncareinc.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Physicians of Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisela Silva</last_name>
      <phone>562-421-2757</phone>
      <email>marisela@eplb.com</email>
    </contact>
    <contact_backup>
      <last_name>Martha Cazares</last_name>
      <phone>(562) 421-2757</phone>
      <email>marthac@eplb.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos E Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James W Donovan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Johnson</last_name>
      <phone>651-275-3077</phone>
      <email>pjohnson@associatedeyecare.com</email>
    </contact>
    <investigator>
      <last_name>Stephen S Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Specialty Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sanford</last_name>
      <phone>901-685-2200</phone>
      <phone_ext>683</phone_ext>
      <email>MichaelSanford@esg.md</email>
    </contact>
    <investigator>
      <last_name>Subba Gollamudi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>January 2, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
